GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sagent Pharmaceuticals Inc (NAS:SGNT) » Definitions » PE Ratio without NRI

Sagent Pharmaceuticals (Sagent Pharmaceuticals) PE Ratio without NRI : At Loss (As of Apr. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sagent Pharmaceuticals PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-04-26), Sagent Pharmaceuticals's share price is $21.76. Sagent Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.77. Therefore, Sagent Pharmaceuticals's PE Ratio without NRI for today is At Loss.

Sagent Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2016 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.77.

As of today (2024-04-26), Sagent Pharmaceuticals's share price is $21.76. Sagent Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.77. Therefore, Sagent Pharmaceuticals's PE Ratio for today is At Loss.

Sagent Pharmaceuticals's EPS (Diluted) for the three months ended in Jun. 2016 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.77.

Sagent Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2016 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.77.


Sagent Pharmaceuticals PE Ratio without NRI Historical Data

The historical data trend for Sagent Pharmaceuticals's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagent Pharmaceuticals PE Ratio without NRI Chart

Sagent Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
PE Ratio without NRI
Get a 7-Day Free Trial At Loss At Loss 25.64 22.22 At Loss

Sagent Pharmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.01 21.90 N/A N/A N/A

Competitive Comparison of Sagent Pharmaceuticals's PE Ratio without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Sagent Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagent Pharmaceuticals's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sagent Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sagent Pharmaceuticals's PE Ratio without NRI falls into.



Sagent Pharmaceuticals PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Sagent Pharmaceuticals's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=21.76/-0.770
=-28.26(At Loss)

Sagent Pharmaceuticals's Share Price of today is $21.76.
Sagent Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Sagent Pharmaceuticals  (NAS:SGNT) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Sagent Pharmaceuticals PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Sagent Pharmaceuticals's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagent Pharmaceuticals (Sagent Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sagent Pharmaceuticals Inc is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.
Executives
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Vivo Ventures V, Llc 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Vivo Ventures V Affiliates Fund, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALO ALTO CA 94301
Vivo Ventures Fund V, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Jonathon M Singer officer: EVP and CFO 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Michael Fekete director C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG IL 60195
Robert J Flanagan director C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG IL 60195
Sean Brynjelsen officer: EVP, Business Development C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
Vivo Ventures Vi Affiilates Fund, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALP ALTO CALIFORNIA CA 94301
Vivo Ventures Fund Vi, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALO ALTO CA 94301
Vivo Ventures Vi, Llc 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Frank Kung director C/O VIVO CAPITAL, 505, PALO ALTO CA 94301
Jeffrey Yordon director
Morgan Stanley Investment Management Inc 10 percent owner 1221 AVENUE OF AMERICAS, NEW YORK NY 10020
Ronald Pauli officer: Chief Financial Officer 2730 WILSHIRE BLVD., #500, LOS ANGELES CA 90403

Sagent Pharmaceuticals (Sagent Pharmaceuticals) Headlines

No Headlines